NYSE:BCSFBain Capital Specialty Finance Competitors & Alternatives

Verra Mobility (NASDAQ:VRRM) and Bain Capital Specialty Finance (NYSE:BCSF) are both small-cap industrial products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Verra Mobility and Bain Capital Specialty Finance, as provided by MarketBeat.com.

Verra Mobility currently has a consensus price target of $13.50, indicating a potential upside of 37.20%. Bain Capital Specialty Finance has a consensus price target of $12.1429, indicating a potential upside of 17.44%. Given Verra Mobility's stronger consensus rating and higher probable upside, research analysts clearly believe Verra Mobility is more favorable than Bain Capital Specialty Finance.

Volatility & Risk

Verra Mobility has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Bain Capital Specialty Finance has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.

Insider & Institutional Ownership

91.3% of Verra Mobility shares are held by institutional investors. Comparatively, 52.2% of Bain Capital Specialty Finance shares are held by institutional investors. 0.9% of Verra Mobility shares are held by insiders. Comparatively, 0.4% of Bain Capital Specialty Finance shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Verra Mobility and Bain Capital Specialty Finance's revenue, earnings per share (EPS) and valuation.

Bain Capital Specialty Finance has lower revenue, but higher earnings than Verra Mobility. Bain Capital Specialty Finance is trading at a lower price-to-earnings ratio than Verra Mobility, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Verra Mobility and Bain Capital Specialty Finance's net margins, return on equity and return on assets.

Summary

Verra Mobility beats Bain Capital Specialty Finance on 11 of the 14 factors compared between the two stocks.

AdaptHealth (NASDAQ:AHCO) and Bain Capital Specialty Finance (NYSE:BCSF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Profitability

This table compares AdaptHealth and Bain Capital Specialty Finance's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for AdaptHealth and Bain Capital Specialty Finance, as provided by MarketBeat.

AdaptHealth currently has a consensus price target of $19.80, suggesting a potential upside of 5.32%. Bain Capital Specialty Finance has a consensus price target of $12.1429, suggesting a potential upside of 17.44%. Given Bain Capital Specialty Finance's higher probable upside, analysts clearly believe Bain Capital Specialty Finance is more favorable than AdaptHealth.

Risk & Volatility

AdaptHealth has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Comparatively, Bain Capital Specialty Finance has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.

Earnings & Valuation

This table compares AdaptHealth and Bain Capital Specialty Finance's top-line revenue, earnings per share and valuation.

Bain Capital Specialty Finance has lower revenue, but higher earnings than AdaptHealth. Bain Capital Specialty Finance is trading at a lower price-to-earnings ratio than AdaptHealth, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

53.9% of AdaptHealth shares are held by institutional investors. Comparatively, 52.2% of Bain Capital Specialty Finance shares are held by institutional investors. 10.9% of AdaptHealth shares are held by insiders. Comparatively, 0.4% of Bain Capital Specialty Finance shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bain Capital Specialty Finance (NYSE:BCSF) and GS ACQUISITION /SH CL A (NYSE:GSAH) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Bain Capital Specialty Finance and GS ACQUISITION /SH CL A's gross revenue, earnings per share (EPS) and valuation.

Bain Capital Specialty Finance has higher revenue and earnings than GS ACQUISITION /SH CL A.

Institutional and Insider Ownership

52.2% of Bain Capital Specialty Finance shares are held by institutional investors. Comparatively, 46.7% of GS ACQUISITION /SH CL A shares are held by institutional investors. 0.4% of Bain Capital Specialty Finance shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Bain Capital Specialty Finance and GS ACQUISITION /SH CL A, as provided by MarketBeat.

Bain Capital Specialty Finance currently has a consensus price target of $12.1429, indicating a potential upside of 17.44%. Given Bain Capital Specialty Finance's higher possible upside, research analysts plainly believe Bain Capital Specialty Finance is more favorable than GS ACQUISITION /SH CL A.

Risk & Volatility

Bain Capital Specialty Finance has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, GS ACQUISITION /SH CL A has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500.

Profitability

This table compares Bain Capital Specialty Finance and GS ACQUISITION /SH CL A's net margins, return on equity and return on assets.

Summary

Bain Capital Specialty Finance beats GS ACQUISITION /SH CL A on 8 of the 11 factors compared between the two stocks.

HAYMAKER ACQUIS/SH CL A (NASDAQ:HYAC) and Bain Capital Specialty Finance (NYSE:BCSF) are both small-cap unclassified companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for HAYMAKER ACQUIS/SH CL A and Bain Capital Specialty Finance, as reported by MarketBeat.com.

Bain Capital Specialty Finance has a consensus target price of $12.1429, indicating a potential upside of 17.44%. Given Bain Capital Specialty Finance's higher possible upside, analysts plainly believe Bain Capital Specialty Finance is more favorable than HAYMAKER ACQUIS/SH CL A.

Valuation & Earnings

This table compares HAYMAKER ACQUIS/SH CL A and Bain Capital Specialty Finance's top-line revenue, earnings per share (EPS) and valuation.

Bain Capital Specialty Finance has higher revenue and earnings than HAYMAKER ACQUIS/SH CL A.

Insider and Institutional Ownership

56.5% of HAYMAKER ACQUIS/SH CL A shares are held by institutional investors. Comparatively, 52.2% of Bain Capital Specialty Finance shares are held by institutional investors. 0.4% of Bain Capital Specialty Finance shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares HAYMAKER ACQUIS/SH CL A and Bain Capital Specialty Finance's net margins, return on equity and return on assets.

Summary

Bain Capital Specialty Finance beats HAYMAKER ACQUIS/SH CL A on 6 of the 8 factors compared between the two stocks.

FORUM MERGER II/SH CL A (NASDAQ:FMCI) and Bain Capital Specialty Finance (NYSE:BCSF) are both small-cap unclassified companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares FORUM MERGER II/SH CL A and Bain Capital Specialty Finance's net margins, return on equity and return on assets.

Insider and Institutional Ownership

70.0% of FORUM MERGER II/SH CL A shares are held by institutional investors. Comparatively, 52.2% of Bain Capital Specialty Finance shares are held by institutional investors. 21.7% of FORUM MERGER II/SH CL A shares are held by insiders. Comparatively, 0.4% of Bain Capital Specialty Finance shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

FORUM MERGER II/SH CL A has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Bain Capital Specialty Finance has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for FORUM MERGER II/SH CL A and Bain Capital Specialty Finance, as provided by MarketBeat.

Bain Capital Specialty Finance has a consensus target price of $12.1429, indicating a potential upside of 17.44%. Given Bain Capital Specialty Finance's higher probable upside, analysts plainly believe Bain Capital Specialty Finance is more favorable than FORUM MERGER II/SH CL A.

Earnings and Valuation

This table compares FORUM MERGER II/SH CL A and Bain Capital Specialty Finance's revenue, earnings per share and valuation.

Bain Capital Specialty Finance has higher revenue and earnings than FORUM MERGER II/SH CL A.

Summary

Bain Capital Specialty Finance beats FORUM MERGER II/SH CL A on 7 of the 10 factors compared between the two stocks.

Global Cord Blood (NYSE:CO) and Bain Capital Specialty Finance (NYSE:BCSF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Global Cord Blood and Bain Capital Specialty Finance, as provided by MarketBeat.com.

Bain Capital Specialty Finance has a consensus price target of $12.1429, indicating a potential upside of 17.44%. Given Bain Capital Specialty Finance's higher possible upside, analysts plainly believe Bain Capital Specialty Finance is more favorable than Global Cord Blood.

Volatility & Risk

Global Cord Blood has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Bain Capital Specialty Finance has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Institutional & Insider Ownership

15.3% of Global Cord Blood shares are owned by institutional investors. Comparatively, 52.2% of Bain Capital Specialty Finance shares are owned by institutional investors. 0.4% of Bain Capital Specialty Finance shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Global Cord Blood and Bain Capital Specialty Finance's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Global Cord Blood and Bain Capital Specialty Finance's gross revenue, earnings per share and valuation.

Bain Capital Specialty Finance has higher revenue and earnings than Global Cord Blood.

Summary

Bain Capital Specialty Finance beats Global Cord Blood on 8 of the 12 factors compared between the two stocks.